Oxford Session 1: Opportunity recognition and construction

  • Saïd Business School, University of Oxford Park End Street, OX1 1HP Oxford, United Kingdom OX1 1HP United Kingdom

The Science Innovation Union is offering a groundbreaking bio-entrepreneurship course aimed directly at the UK’s top scientists and budding entrepreneurs. The programme consists of a series of four exciting sessions lead by high profile leading academics and industry experts. Head to our website to sign up now! http://science-union.org/siu360-application

Links to other three session in the SIU360 series:
Session 2: https://www.facebook.com/events/1282123598478793/
Session 3: https://www.facebook.com/events/103430890126308/
Session 4: https://www.facebook.com/events/359868271018146/

Session 1: Opportunity recognition and construction.
For those individuals at the start of their entrepreneurial career, one of the most difficult challenges is to learn how to spot opportunities that are worth chasing. Is there a demand? Is the proposed solution appropriate and economically viable? Is the timing right? Is the technology protectable from an IP point of view? This list of questions, which is far from exhaustive, are all questions which clearly need to be addressed, however the answers are not always obvious. Attendees will acquire knowledge and skills which will aid them in their assessment of opportunities and allow them to make better decisions when considering which ideas represent realistic and compelling opportunities.

Speaker: Chas Bountra is Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at Imperial College, London. He is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.

Prior to coming back to Oxford, Chas Bountra was Vice President and Head of Biology at GlaxoSmithKline. He was involved in the identification of more than 40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases.